AbbVie and Regenxbio have entered into a partnership to develop and commercialize RGX-314, an investigational gene therapy, for the treatment of retinal diseases, according to a press release.
Regenxbio will be responsible for completing ongoing trials, and the companies will collaborate on future trials, including a second pivotal trial investigating the treatment for wet age-related macular degeneration.
AbbVie will make an upfront payment of $370 million to Regenxbio, which may be eligible to receive up to $1.38 billion in development, regulatory and commercial milestones, the release said.